PharmaNutra S.p.A. · MIL:PHN
PharmaNutra — Q3 2022 Earnings Presentation
22 slides from PharmaNutra's earnings presentation, Nov 7, 2022
Slide 1: Q3 2022 Financial Results
Q3_2022 FINANCIAL RESULTS November 7th, 2022
Slide 2: Disclaimer
2 DISCLAIMER This document has been prepared by Pharmanutra S.p.A. (the “Company”) for use during meetings with investors and financial analyst and is solely for information purposes. It contains solely data and information provided by the Company or already in the public domain. This Document may n
Slide 3: Group Presentation & Highlights Q3 2022
GROUP PRESENTATION & HIGHLIGHTS Q3 2022
Slide 4: PharmaNutra Group
4 PHARMANUTRA 2022 GROUP Research and development of bioimpedance medical devices and software for body composition analysis PharmaNutra holds 100% of 2010 Junia Pharma and Alesco and since end of July 2022 86,48% of Medical products and devices, OTC and dietary Akern’s share capital. supplements fo
Slide 5: Highlights Q3 2022
5 HIGHLIGHTS Q3 2022 ▪ The first closing relating to the acquisition of an overall stake equal to 86.48% of the share capital of Akern was finalized on July 26th ▪ Launch of the new Cetilar® Oro and ApportAL® Vital food supplements representing an important extension of the Cetilar® and ApportAL® li
Slide 6: Economic and Financial Data
6 ECONOMIC AND FINANCIAL DATA
Slide 7: Highlights Q3 - 2022
7 HIGHLIGHTS Q3 - 2022 + 22% NET REVENUES € 60,3 M (+22% COMPARE TO Q3 2021) ▪ 22% Increase in Net Sales Revenues EBITDA € 19,1 M ▪ 21% EBITDA Growth + 21% (31,7% MARGIN ON NET REVENUES) ▪ 31,7% EBITDA Margin on Net Revenues ▪ 23%* Net Result increase NET RESULT € 12,8 M + 23%* (21,2% MARGIN ON REVE
Slide 8: Net Revenues
8 NET REVENUES Net revenues at 30.09.2022 accounted for € 60.3 million, recording a growth of 22% compared to the previous year both on the domestic market and on the foreign market. Akern’s net revenues (as of July 1st) accounted for € 0,9 million, about 1,5% on the total net revenues of the Group.
Slide 9: Profit and Loss
9 PROFIT AND LOSS PROFIT AND LOSS (€/000) 30/09/2022 30/09/2021 REVENUES A) REVENUES 60.542 49.672 Net Revenues 60.270 49.306 Consolidated revenues accounted for € 60,3 million with an increase of Other revenues 272 366 22% compared to the same period of the previous year. The increase is due to the
Slide 10: Reclassified Consolidated Balance Sheet
10 RECLASSIFIED CONSOLIDATED BALANCE SHEET Amounts in €/000 30/09/2022 31/12/2021 ∆ 2022 vs 2021 Trade Receivables Trade receivables 23.347 16.673 6.674 The increase in trade receivables is due to higher revenues Inventories 4.440 2.865 1.575 Other Receivables/Other Payables Trade Payables (11.342)
Slide 11: Akern Income Statements
11 AKERN INCOME STATEMENTS 30/09/2022 Akern’s consolidation process started as of July 1st, 2022. AKERN PROFIT AND LOSS (€/000) Q3 2022 YTD AKERN BALANCE SHEET (€) 30/09/2022 A) REVENUES 3.273 910 Net Revenues 3.223 906 Trade receivables 356 Other revenues 50 4 Inventories 531 Trade Payables (298) B
Slide 12: Consolidated Cash Flow
12 CONSOLIDATED CASH FLOW Cash Flow (€/000) 30/09/2022 30/09/2021 Net Result 12.646 10.886 CASH FROM OPERATING ACTIVITIES NON MONETARY EXPENSES Change in operating working capital Amortization, depreciation and w.o. 920 885 Increase in trade receivables due to higher revenues and sales volumes. Accr
Slide 13: Net Financial Position
13 NET FINANCIAL POSITION NFP The Net Financial Position at 30.09.2022 accounted for € 7,3 million. The decrease compared to 31.12.2021 is mainly due to the acquisition of Akern (€ 10,1 million), to capital expenditures related to the construction of the new Headquarter and other capex (€ 6,9 millio
Slide 14: Market
MARKET @PHARMANUTRA ~. ™ ™N SE™®™ ass
Slide 15: Iron Supplements SiderAL Market Share in Italy
15 IRON SUPPLEMENTS SIDERAL® MARKET SHARE IN ITALY Excluding products that contain only lactoferrin Source IQVIA
Slide 16: Anti-Inflammatory Topical Cream Cetilar Market Share in Italy
16 ANTI-INFLAMMATORY TOPICAL CREAM CETILAR® MARKET SHARE IN ITALY Source IQVIA
Slide 17: ApportAL Compared to the Reference Markets
17 APPORTAL® COMPARED TO THE REFERENCE MARKETS Source IQVIA
Slide 18: International Development
18 INTERNATIONAL DEVELOPMENT COUNTRIES PARTNERS Contracts 67 45 Active Sales 59 39 On-going Registration 8 6 On-going Negotiation 7 9
Slide 19: Cross Border Ecommerce China
19 CINA CROSS BORDER ECOMMERCE CHINA ▪ Cross Border e-commerce is an increasingly significant component of China’s economy and its growing share of foreign trade; in 2021 the import-export market is worth 1.92 trillion yuan (about $284.5 billion); ▪ New store with the range of SiderAL® brand product
Slide 20: Outlook 2022
OUTLOOK 2022 Q@PHARMANUTRA
Slide 21: Outlook 2022
21 OUTLOOK 2022 ▪ The results obtained in the first nine months of 2022, the sales trend on the Italian market and the orders relating to the foreign markets in the fourth quarter will allow us to confirm results in line with expectations; ▪ The Product strategy of the Group is aimed at strengthenin
Slide 22: PharmaNutra
MPHARMANUTRA